Gilead Sciences, Inc (GIS) Stock Price & News

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

About Gilead Sciences, Inc

CEODaniel O'Day

Employees17K

FoundedJun 22, 1987

HeadquartersFoster City, California, United States

SectorBiotechnology

Websitegilead.com

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	7.77B	7.92B	6.96B	7.80B
Cost of goods sold	1.57B	1.62B	1.44B	1.58B
Cost of revenue	1.57B	1.62B	1.44B	1.58B
Research and development expenses	1.33B	1.57B	1.36B	1.69B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.35B	1.78B	1.43B	1.91B
Operating expense	2.69B	3.34B	2.78B	3.60B
Total operating expenses	4.26B	4.96B	4.23B	5.18B
Operating income	3.51B	2.96B	2.73B	2.63B
Other non operating income	-23.00M	51.00M	-8.00M	-
EBT including unusual items	3.64B	2.08B	2.58B	-10.25B
EBT excluding unusual items	3.34B	2.80B	2.59B	2.42B
Income tax expense	589.00M	-105.00M	559.00M	242.00M
Effective tax rate	16.18%	-5.05%	21.67%	-2.36%
Other operating expenses	-	-	-	-
Net income	3.05B	2.18B	2.02B	-10.50B
Net profit margin	39.28%	27.55%	29.04%	-134.51%
Earnings per share	2.47	1.86	2.03	-6.75
Interest and investment income	88.00M	95.00M	95.00M	45.00M
Interest expense	-256.00M	-255.00M	-240.00M	-247.00M
Net interest expenses	-168.00M	-160.00M	-145.00M	-202.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	4.20B	3.65B	3.42B	3.33B
Gain or loss from assets sale	-	-	-	-

Ask anything